why choose us

First received: November 03, 2025

Clinical Trial: Forecasting Occult liveR Metastasis Using an Exosomal Signature for Intelligent Guided Hepatic Targeting

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: PDAC - Pancreatic Ductal Adenocarcinoma

Study Type: OBSERVATIONAL


Official Title: An Exosome-based Liquid Biopsy Signature for Preoperative Identification of Occult Liver Metastasis in Patients With Pancreatic Ductal Adenocarcinoma

Brief Summary: Early liver metastasis (Early-LiM) is the most significant prognostic factor in pancreatic ductal adenocarcinoma (PDAC) and is thought to originate from occult micrometastases present at the time of surgery.Reliable preoperative detection of such lesions remains an unmet clinical need.The EXELiM study aims to develop and validate a circulating exosomal microRNA (exo-miRNA)-based liquid biopsy assay to accurately identify PDAC patients at high risk of occult liver metastasis before surgery.By integrating machine…

Read more